Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BioMarin, Spark Hemophilia Gene Therapies Progress As Accelerated Approval Favors Their Indications

May 23 2018

• By Mandy Jackson

RedBloodCellsOnWhite_1200x675

Related Content

Gene Therapy Guidances From US FDA Coming In About 6 Weeks, Gottlieb Says

May 11 2018

Spark Plots Rebound For Hemophilia A Gene Therapy, As Rival BioMarin Surges

Dec 12 2017

Gene therapy rising: Bluebird soars at ASH, Pfizer builds platform

Dec 09 2014

Related Companies

BioMarin Pharmaceutical Inc.

Spark Therapeutics, Inc.

Pfizer Inc.

Additional Topics

Clinical Trials Drug Approval Standards Policy Rare Diseases Research & Development Blood & Coagulation Disorders BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window